News

FDA will increase postmarketing surveillance of drugs

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7476.1203-a (Published 18 November 2004) Cite this as: BMJ 2004;329:1203
  1. Janice Hopkins Tanne
  1. New York

    After controversies about the possible increased risk of suicide in children taking antidepressants and the increase in heart attacks and strokes in patients taking rofecoxib (Vioxx, MSD), the US Food and Drug Administration has announced plans to strengthen its surveillance of drugs on the market.


    Embedded Image

    Dr Lester …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe